THE COST OF ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT IN CHILDREN USING COMBINED CHEMOTHERAPY AND IMMUNOTHERAPY: COMPARISON OF ESTIMATED AND REAL VALUES

Yu. A. Shifrin(Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology), Aleksandr I. Karachunskiy(Research Medical Center), Д. С. Блинов(Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology), Alexandra Shutova(Research Medical Center), E. A. Tuzova(Research Medical Center), Anna A. Mahrova(Research Medical Center)
Acta medica Eurasica
March 28, 2024
10.47026/2413-4864-2024-1-38-49
Cited by 2

Related Papers

Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-l1 Treatment Assessment
|Cells|2019|19
Novel Hydroxypyridine Compound Protects Brain Cells against Ischemic Damage In Vitro and In Vivo
|International Journal of Molecular Sciences|2022|16
Novel aminochromone derivative inhibits tumor growth on xenograft model of lung cancer in mice
|Journal of Advanced Pharmaceutical Technology amp Research|2018|14
Prognostic Role of FGFR3 Expression Status and Tumor-Related MicroRNAs Level in Association with PD-L1 Expression in Primary Luminal Non-Muscular Invasive Bladder Carcinoma
|Life|2020|13
Anticancer signal transduction pathways of selenium nanoparticles in mouse colorectal cancer model
|Biochemical and Biophysical Research Communications|2025|12